ID

30395

Beschreibung

Se-Methyl-Seleno-L-Cysteine, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment; ODM derived from: https://clinicaltrials.gov/show/NCT00829205

Link

https://clinicaltrials.gov/show/NCT00829205

Stichworte

  1. 02.06.18 02.06.18 -
Rechteinhaber

See clinicaltrials.gov

Hochgeladen am

2. Juni 2018

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0

Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Lymphoma NCT00829205

Eligibility Lymphoma NCT00829205

  1. StudyEvent: Eligibility
    1. Eligibility Lymphoma NCT00829205
Criteria
Beschreibung

Criteria

histologically confirmed, cd20+, diffuse large b-cell lymphoma (dlbcl) according to who lymphoma classification
Beschreibung

Diffuse Large B-Cell Lymphoma CD20 positive WHO tumor classification

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0079744
UMLS CUI [1,2]
C0882818
UMLS CUI [1,3]
C1301142
histological transformation of a previously known indolent lymphoma allowed
Beschreibung

Indolent Lymphoma Transformation

Datentyp

boolean

Alias
UMLS CUI [1,1]
C1334170
UMLS CUI [1,2]
C1536010
biopsy-proven dlbcl arising from an indolent lymphoma not diagnosed previously allowed
Beschreibung

Diffuse Large B-Cell Lymphoma Origin Indolent Lymphoma

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0079744
UMLS CUI [1,2]
C0439659
UMLS CUI [1,3]
C1334170
disease in first relapse after complete remission, partial response (pr), or less than a pr after first-line of treatment
Beschreibung

First Relapse Post Complete remission | Partial response | Less Than Partial response Post First line treatment

Datentyp

boolean

Alias
UMLS CUI [1,1]
C4054953
UMLS CUI [1,2]
C0687676
UMLS CUI [1,3]
C0677874
UMLS CUI [2]
C1521726
UMLS CUI [3,1]
C0439092
UMLS CUI [3,2]
C1521726
UMLS CUI [3,3]
C0687676
UMLS CUI [3,4]
C1708063
no primary cns lymphoma
Beschreibung

Primary central nervous system lymphoma Absent

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0280803
UMLS CUI [1,2]
C0332197
patient characteristics:
Beschreibung

Client Characteristics

Datentyp

boolean

Alias
UMLS CUI [1]
C0815172
ecog performance status 0-2
Beschreibung

ECOG performance status

Datentyp

boolean

Alias
UMLS CUI [1]
C1520224
life expectancy > 3 months
Beschreibung

Life Expectancy

Datentyp

boolean

Alias
UMLS CUI [1]
C0023671
serum creatinine < 150 μmol/l
Beschreibung

Creatinine measurement, serum

Datentyp

boolean

Alias
UMLS CUI [1]
C0201976
serum bilirubin < 35 μmol/l
Beschreibung

Serum total bilirubin measurement

Datentyp

boolean

Alias
UMLS CUI [1]
C1278039
transaminases < 2.5 times upper limit of normal (unless attributed to lymphoma)
Beschreibung

Transaminase Assay | Exception Relationship Lymphoma

Datentyp

boolean

Alias
UMLS CUI [1]
C0919834
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0439849
UMLS CUI [2,3]
C0024299
not pregnant or nursing
Beschreibung

Pregnancy Absent | Breast Feeding Absent

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0032961
UMLS CUI [1,2]
C0332197
UMLS CUI [2,1]
C0006147
UMLS CUI [2,2]
C0332197
negative pregnancy test
Beschreibung

Pregnancy test negative

Datentyp

boolean

Alias
UMLS CUI [1]
C0427780
fertile patients must use effective contraception
Beschreibung

Fertility Contraceptive methods

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0015895
UMLS CUI [1,2]
C0700589
no contraindication to any of the drugs contained in the immunochemotherapy regimen
Beschreibung

Exclusion | Medical contraindication Pharmaceutical Preparations Immunochemotherapy

Datentyp

boolean

Alias
UMLS CUI [1]
C2828389
UMLS CUI [2,1]
C1301624
UMLS CUI [2,2]
C0013227
UMLS CUI [2,3]
C4087148
no other malignancy within the past 2 years, except basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix
Beschreibung

Exclusion Cancer Other | Exception Basal cell carcinoma | Exception Squamous cell carcinoma of skin | Exception Carcinoma in situ of uterine cervix

Datentyp

boolean

Alias
UMLS CUI [1,1]
C2828389
UMLS CUI [1,2]
C1707251
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0007117
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0553723
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C0851140
no other serious active disease that, in the opinion of the investigator, would preclude the patient from having conventional chemotherapy
Beschreibung

Exclusion | Disease Serious Preventing Chemotherapy

Datentyp

boolean

Alias
UMLS CUI [1]
C2828389
UMLS CUI [2,1]
C0012634
UMLS CUI [2,2]
C0205404
UMLS CUI [2,3]
C1292733
UMLS CUI [2,4]
C0392920
no hiv positivity
Beschreibung

Exclusion HIV Seropositivity

Datentyp

boolean

Alias
UMLS CUI [1,1]
C2828389
UMLS CUI [1,2]
C0019699
no medical or psychiatric conditions that compromise the patient's ability to give informed consent
Beschreibung

Exclusion Criteria | Medical condition compromises Informed Consent | Mental condition compromises Informed Consent

Datentyp

boolean

Alias
UMLS CUI [1]
C0680251
UMLS CUI [2,1]
C3843040
UMLS CUI [2,2]
C2945640
UMLS CUI [2,3]
C0021430
UMLS CUI [3,1]
C3840291
UMLS CUI [3,2]
C2945640
UMLS CUI [3,3]
C0021430
prior concurrent therapy:
Beschreibung

Therapeutic procedure

Datentyp

boolean

Alias
UMLS CUI [1]
C0087111
not specified
Beschreibung

Unspecified

Datentyp

boolean

Alias
UMLS CUI [1]
C0205370

Ähnliche Modelle

Eligibility Lymphoma NCT00829205

  1. StudyEvent: Eligibility
    1. Eligibility Lymphoma NCT00829205
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
Diffuse Large B-Cell Lymphoma CD20 positive WHO tumor classification
Item
histologically confirmed, cd20+, diffuse large b-cell lymphoma (dlbcl) according to who lymphoma classification
boolean
C0079744 (UMLS CUI [1,1])
C0882818 (UMLS CUI [1,2])
C1301142 (UMLS CUI [1,3])
Indolent Lymphoma Transformation
Item
histological transformation of a previously known indolent lymphoma allowed
boolean
C1334170 (UMLS CUI [1,1])
C1536010 (UMLS CUI [1,2])
Diffuse Large B-Cell Lymphoma Origin Indolent Lymphoma
Item
biopsy-proven dlbcl arising from an indolent lymphoma not diagnosed previously allowed
boolean
C0079744 (UMLS CUI [1,1])
C0439659 (UMLS CUI [1,2])
C1334170 (UMLS CUI [1,3])
First Relapse Post Complete remission | Partial response | Less Than Partial response Post First line treatment
Item
disease in first relapse after complete remission, partial response (pr), or less than a pr after first-line of treatment
boolean
C4054953 (UMLS CUI [1,1])
C0687676 (UMLS CUI [1,2])
C0677874 (UMLS CUI [1,3])
C1521726 (UMLS CUI [2])
C0439092 (UMLS CUI [3,1])
C1521726 (UMLS CUI [3,2])
C0687676 (UMLS CUI [3,3])
C1708063 (UMLS CUI [3,4])
Primary central nervous system lymphoma Absent
Item
no primary cns lymphoma
boolean
C0280803 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
Client Characteristics
Item
patient characteristics:
boolean
C0815172 (UMLS CUI [1])
ECOG performance status
Item
ecog performance status 0-2
boolean
C1520224 (UMLS CUI [1])
Life Expectancy
Item
life expectancy > 3 months
boolean
C0023671 (UMLS CUI [1])
Creatinine measurement, serum
Item
serum creatinine < 150 μmol/l
boolean
C0201976 (UMLS CUI [1])
Serum total bilirubin measurement
Item
serum bilirubin < 35 μmol/l
boolean
C1278039 (UMLS CUI [1])
Transaminase Assay | Exception Relationship Lymphoma
Item
transaminases < 2.5 times upper limit of normal (unless attributed to lymphoma)
boolean
C0919834 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0439849 (UMLS CUI [2,2])
C0024299 (UMLS CUI [2,3])
Pregnancy Absent | Breast Feeding Absent
Item
not pregnant or nursing
boolean
C0032961 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C0006147 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
Pregnancy test negative
Item
negative pregnancy test
boolean
C0427780 (UMLS CUI [1])
Fertility Contraceptive methods
Item
fertile patients must use effective contraception
boolean
C0015895 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
Exclusion | Medical contraindication Pharmaceutical Preparations Immunochemotherapy
Item
no contraindication to any of the drugs contained in the immunochemotherapy regimen
boolean
C2828389 (UMLS CUI [1])
C1301624 (UMLS CUI [2,1])
C0013227 (UMLS CUI [2,2])
C4087148 (UMLS CUI [2,3])
Exclusion Cancer Other | Exception Basal cell carcinoma | Exception Squamous cell carcinoma of skin | Exception Carcinoma in situ of uterine cervix
Item
no other malignancy within the past 2 years, except basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix
boolean
C2828389 (UMLS CUI [1,1])
C1707251 (UMLS CUI [1,2])
C1705847 (UMLS CUI [2,1])
C0007117 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0553723 (UMLS CUI [3,2])
C1705847 (UMLS CUI [4,1])
C0851140 (UMLS CUI [4,2])
Exclusion | Disease Serious Preventing Chemotherapy
Item
no other serious active disease that, in the opinion of the investigator, would preclude the patient from having conventional chemotherapy
boolean
C2828389 (UMLS CUI [1])
C0012634 (UMLS CUI [2,1])
C0205404 (UMLS CUI [2,2])
C1292733 (UMLS CUI [2,3])
C0392920 (UMLS CUI [2,4])
Exclusion HIV Seropositivity
Item
no hiv positivity
boolean
C2828389 (UMLS CUI [1,1])
C0019699 (UMLS CUI [1,2])
Exclusion Criteria | Medical condition compromises Informed Consent | Mental condition compromises Informed Consent
Item
no medical or psychiatric conditions that compromise the patient's ability to give informed consent
boolean
C0680251 (UMLS CUI [1])
C3843040 (UMLS CUI [2,1])
C2945640 (UMLS CUI [2,2])
C0021430 (UMLS CUI [2,3])
C3840291 (UMLS CUI [3,1])
C2945640 (UMLS CUI [3,2])
C0021430 (UMLS CUI [3,3])
Therapeutic procedure
Item
prior concurrent therapy:
boolean
C0087111 (UMLS CUI [1])
Unspecified
Item
not specified
boolean
C0205370 (UMLS CUI [1])

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video